{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:55:26Z","timestamp":1791179726493,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T00:00:00Z","timestamp":1428883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0122300","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T18:43:50Z","timestamp":1429123430000},"page":"e0122300","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography"],"prefix":"10.1371","volume":"10","author":[{"given":"Ming Li","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Avory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Burnouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,4,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410350404","article-title":"Human prion diseases","volume":"35","author":"SB Prusiner","year":"1994","journal-title":"Ann Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.278.5336.245","article-title":"Prion diseases and the BSE crisis","volume":"278","author":"SB Prusiner","year":"1997","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e94020","DOI":"10.1371\/journal.pone.0094020","article-title":"Estimation of the Exposure of the UK Population to the Bovine Spongiform Encephalopathy Agent through Dietary Intake During the Period 1980 to 1996","volume":"9","author":"CC Chen","year":"2014","journal-title":"PLoS One"},{"key":"ref4","unstructured":"Anonymous (2011) Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA\/410\/01 rev.3). In: Commission E, editor. Official Journal of the European Union."},{"key":"ref5","article-title":"Transmissible Spongiform Encephalopathies. Managing risk in mammalian organs, cells and sera. 15\u201316 March 1999, San Diego, CA, USA","volume":"2","author":"AC Bailey","year":"1999","journal-title":"IDrugs: the investigational drugs journal"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e1002651","DOI":"10.1371\/journal.ppat.1002651","article-title":"Five questions on prion diseases","volume":"8","author":"A Aguzzi","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10616-013-9633-8","article-title":"A plea to reduce or replace fetal bovine serum in cell culture media","volume":"65","author":"G Gstraunthaler","year":"2013","journal-title":"Cytotechnology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3727\/096368912X653138","article-title":"Supplements in human islet culture: human serum albumin is inferior to fetal bovine serum","volume":"21","author":"ES Avgoustiniatos","year":"2012","journal-title":"Cell Transplant"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000321166","article-title":"Guidance for removal of fetal bovine serum from cryopreserved heart valve processing","volume":"193","author":"KG Brockbank","year":"2011","journal-title":"Cells Tissues Organs"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/026119290203000208","article-title":"The use of fetal bovine serum: ethical or scientific problem?","volume":"30","author":"CE Jochems","year":"2002","journal-title":"Altern Lab Anim"},{"key":"ref11","unstructured":"WHO (2006) WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/bloodproducts\" xlink:type=\"simple\">http:\/\/www.who.int\/bloodproducts<\/ext-link>."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1423-0410.2009.01206.x","article-title":"Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent\/detergent (S\/D)-treated plasma OctaplasLG","volume":"97","author":"A Neisser-Svae","year":"2009","journal-title":"Vox Sang"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1537-2995.2001.41040449.x","article-title":"A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins","volume":"41","author":"DC Lee","year":"2001","journal-title":"Transfusion"},{"key":"ref14","unstructured":"CPMP (2003) Guideline on the Investigation of Manufacturing Processes for Plasma-Derived Medicinal Products with Regards to vCJD Risk. CPMP\/BWP\/5136\/03 London, UK."},{"key":"ref15","first-page":"237","article-title":"Transmissible encephalopathies and biopharmaceutical production","volume":"88","author":"MM Robinson","year":"1996","journal-title":"Dev Biol Stand"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0021-9975(71)90100-9","article-title":"An experimental examination of the scrapie agent in cell membrane mixtures. II. The association of scrapie activity with membrane fractions","volume":"81","author":"GC Millson","year":"1971","journal-title":"J Comp Pathol"},{"key":"ref17","unstructured":"Anonymous (2010) Qyu Speed D 0.6ml Hollow Fiber Anion Exchange Membrane Adsorber. In: LTD AKMC, editor. Document No TAS33059. Tokyo."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/j.1537-2995.2008.01862.x","article-title":"Quantitative assessment of the kinetics of growth factors release from platelet gel","volume":"48","author":"CY Su","year":"2008","journal-title":"Transfusion"},{"key":"ref19","year":"1998","unstructured":"Anonymous (<year>1998<\/year>) <chapter-title>OECD series on principles of good laboratory practice and compliance monotoring\u2014Principles of Good Laboratory Practice ENV\/MC\/CHEM (98) 17 (revised)<\/chapter-title>. In: <collab xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:type=\"simple\">Development OfEC-oa<\/collab>, editor. <publisher-loc>Paris<\/publisher-loc>: <publisher-name>Organisation for Economic Co-operation and Development<\/publisher-name>."},{"key":"ref20","unstructured":"Anonymous 21 CFR part 58, Good Laboratory Practice, US FDA. In: Organization UFaD, editor. Bethesda, USA."},{"key":"ref21","unstructured":"Anonymous (2006) Austrian BGBl. II, 450\u2014Verordnung, Gute Laborpraxis 2006, Jahrgang 2006. In: BGBl A, editor. II, 450. Vienna, Austria."},{"key":"ref22","article-title":"EU Directive 2004\/9\/EC\u2014Inspection and verification of good laboratory practice (GLP)","year":"2004"},{"key":"ref23","year":"2004","unstructured":"Anonymous (<year>2004<\/year>) <chapter-title>EU Directive 2004\/10\/EC\u2014Regulations and administrative provisions relating to the application of the principles of good laboratory practice (GLP) and the verification of their applications for tests on chemical substances (codified version)<\/chapter-title>. <publisher-loc>Brussels<\/publisher-loc>: <publisher-name>European Commission<\/publisher-name>."},{"key":"ref24","unstructured":"CPMP (1996) Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Inactivation of Viruses. In: Agency EM, editor. CPMP\/BWP\/268\/95 (revised in 1996) London, UK."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"PR Foster","year":"2000","journal-title":"Vox Sang"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0166-0934(99)00135-4","article-title":"Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein","volume":"84","author":"DC Lee","year":"2000","journal-title":"J Virol Methods"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1537-2995.1998.38998408999.x","article-title":"The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy","volume":"38","author":"P Brown","year":"1998","journal-title":"Transfusion"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1423-0410.2002.00211.x","article-title":"Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin","volume":"83","author":"HE Reichl","year":"2002","journal-title":"Vox Sang"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1537-2995.1999.39111169.x","article-title":"Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans","volume":"39","author":"P Brown","year":"1999","journal-title":"Transfusion"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tracli.2006.11.001","article-title":"Current strategies to prevent transmission of prions by human plasma derivatives","volume":"13","author":"T Burnouf","year":"2006","journal-title":"Transfus Clin Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1423-0410.2003.00312.x","article-title":"Evaluation of depth filtration to remove prion challenge from an immune globulin preparation","volume":"85","author":"RW Van Holten","year":"2003","journal-title":"Vox Sang"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0042-9007.2004.00403.x","article-title":"Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII","volume":"86","author":"PR Foster","year":"2004","journal-title":"Vox Sang"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/biol.2002.0327","article-title":"Purity of spiking agent affects partitioning of prions in plasma protein purification","volume":"30","author":"M Vey","year":"2002","journal-title":"Biologicals"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-3148.1999.009001003.x","article-title":"Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy","volume":"9","author":"PR Foster","year":"1999","journal-title":"Transfus Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tiv.2003.08.009","article-title":"The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture","volume":"18","author":"J van der Valk","year":"2004","journal-title":"Toxicol In Vitro"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Shih DT, Burnouf T (2014) Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. N Biotechnol.","DOI":"10.1016\/j.nbt.2014.06.001"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0122300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T14:07:30Z","timestamp":1566569250000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0122300"}},"subtitle":[],"editor":[{"given":"Noriyuki","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,13]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0122300","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,13]]}}}